Article

Depression Common in Axial Spondyloarthritis

When disease activity is high and/or function impaired, consider depression a likely comorbidity that may be a result of inflammation.

Reference1. Zhao S, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20:140. doi: 10.1186/s13075-018-1644-6.

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
Related Content
IV Secukinumab Rapidly Improved Clinical Responses in Psoriatic Arthritis | Image Credit: Altoona Center for Clinical Research
October 12th 2024

IV Secukinumab Rapidly Improved Clinical Responses in Psoriatic Arthritis

Connor Iapoce
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Gout | Credit: Unsplash
October 12th 2024

Increased Dietary Vitamin C Intake May Help Reduce Gout Risk, Study Finds

Abigail Brooks, MA
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Adwoa Dansoa Tabi-Amponsah, PhD candidate, Department of Medicine, The Faculty of Medical and Health Sciences, University of Auckland, New Zealand
October 9th 2024

Simplified Gout Remission Definition Feasible, Valid

Victoria Johnson
Ixekizumab as Effective, if not More Effective as TNFi, JAKi, IL-12/23i for PsA Treatment
October 8th 2024

Ixekizumab as Effective, if not More Effective as TNFi, JAKi, IL-12/23i for PsA Treatment

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.